10 research outputs found
Systemic effects of locally injected platelet rich plasma in a rat model: an analysis on muscle and bloodstream
Ischemia/reperfusion injury is increased and cardioprotection by a postconditioning protocol is lost as cardiac hypertrophy develops in Nandrolone treated rats
Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns.
Prolonged nandrolone treatment modifies heart proteomic profile of rats subjected to acute stress
New hplc–uv validated method for therapeutic drug monitoring of antifungal agents in acute myeloid leukemia
Postconditioning (PostC) cardioprotection in experimental modelsof cardiac hypertrophy: spontaneously hypertensive (SHR) and nandrolone (ND)-abuse rats
Effects of sub-chronic nandrolone administration on hormonal adaptive response to acute stress in rats.
Severe asthma: One disease and multiple definitions
Introduction
There is, so far, no universal definition of severe asthma. This definition usually relies on: number of exacerbations, inhaled therapy, need for oral corticosteroids, and respiratory function. The use of such parameters varies in the different definitions used. Thus, according to the parameters chosen, each patient may result in having severe asthma or not. The aim of this study was to evaluate how the choice of a specific definition of severe asthma can change the allocation of patients.
Methods
Data collected from the Severe Asthma Network Italy (SANI) registry were analyzed. All the patients included were then reclassified according to the definitions of U-BIOPRED, NICE, WHO, ATS/ERS, GINA, ENFUMOSA, and TENOR.
Results
540 patients, were extracted from the SANI database. We observed that 462 (86%) met the ATS/ERS criteria as well as the GINA criteria, 259 (48%) the U-Biopred, 222 (41%) the NICE, 125 (23%) the WHO, 313 (58%) the Enfumosa, and 251 (46%) the TENOR criteria. The mean eosinophil value were similar in the ATS/ERS, U-Biopred, and Enfumosa (528, 532 and 516 cells/mcl), higher in WHO and Tenor (567 and 570 cells/mcl) and much higher in the NICE classification (624 cells/mcl). Lung function tests resulted similarly in all groups, with WHO (67%) and ATS/ERS-GINA (73%), respectively, showing the lower and upper mean FEV1 values.
Conclusions
The present observations clearly evidence the heterogeneity in the distribution of patients when different definitions of severe asthma are used. However, the recent definition of severe asthma, provided by the GINA document, is similar to that indicated in 2014 by ATS/ERS, allowing mirror reclassification of the patients examined. This lack of homogeneity could complicate the access to biological therapies. The definition provided by the GINA document, which reflects what suggested by ATS/ERS, could partially overcome the problem